Inclusion criteria
1. Male or female aged 18 years to 80 years at the time of providing informed consent.
2. Subjects must have documented evidence of a history of atherosclerotic coronary artery disease/surgical revascularization (defined as either a prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft surgery) or peripheral vascular disease (defined by prior percutaneous or surgical peripheral revascularization procedure). Documentation of atherosclerotic disease must be provided. A minimum of 1 month must have elapsed between a subject's randomization and any acute event, revascularization procedure, or hospitalization for chest pain for that subject.
3. Subjects must be taking 2 antiplatelet medications (with appropriate medical indication) with a stable dose for a minimum of 1 month before randomization. These antiplatelet medications must comprise: -Aspirin (75 to 325 mg per day).
-A P2Y12 receptor antagonist, either clopidogrel (75 mg per day) or prasugrel (10 mg per day).
4. Subjects must be on a stable medication regimen for chronically administered therapy for a minimum of 2 weeks or 5 half-lives (whichever is longer) before randomization and must remain on this stable medication regimen throughout the active study period.
5. Body weight 50 kg or greater at screening.
6. Capable of understanding the purposes and risks of the study and able to provide written informed consent before any study-specific screening procedures are performed.
7. Willing and able to adhere to all protocol requirements.
8. Female subjects with a negative urine or serum pregnancy test or who are postmenopausal (menopause is defined as over the age of 60 years, or women between the ages 45 and 60 years who are amenorrheic for at least 1 year and have a folliclestimulating hormone level >30 IU/L). Females of childbearing potential must be practicing adequate birth control during the study and for 3 months after receipt of the study product to be eligible. Acceptable methods of birth control are oral contraceptives, intrauterine device, female and male condoms with foam or spermicidal jelly, diaphragm, contraceptive medication patch, contraceptive medication implant, contraceptive medication injection, abstinence, or surgical sterilization more than 3 months prior to randomization.
9. Male subjects must agree to use effective contraception (i.e., condom with foam or spermicidal jelly, vasectomy, or abstinence) during the study and for 3 months after the receipt of study product.
10. Willing not to participate in another interventional clinical study until completion of the follow-up study period final (Day 90) visit.
Exclusion criteria
1. A history of unexplained syncope, known Long QT syndrome, or Brugada syndrome.
Subjects will also be excluded if there is family history of Long QT syndrome.
2. New York Heart Association class III or IV heart failure or documented cardiac ejection fraction of <35%.
3. Renal function that is moderate or severely impaired (CrCl <60 mL/min) [calculated using the Cockcroft-Gault formula].
4. For subject with diabetes mellitus, recent (within 30 days of admission) unstable glycemic control defined as: >1 hypoglycemic episode, hypoglycemic unawareness, or hyperglycemia requiring hospitalization. 23. Donation or loss of >500 mL of blood within the three months preceding randomization.
24. Participating in another clinical study involving another investigational product or extensive blood sampling within three months of randomization.
25. Subject is pregnant or lactating, or planning to become pregnant during the study period.
26. Any issues that, in the opinion of the investigator, would render the subject unsuitable for study participation.
